Toll Free: 1-888-928-9744

3SBio Inc. - Product Pipeline Review - 2016

Published: May 25, 2016 | Pages: 81 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

3SBio Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, '3SBio Inc. - Product Pipeline Review - 2016', provides an overview of the 3SBio Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by 3SBio Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of 3SBio Inc.
- The report provides overview of 3SBio Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses 3SBio Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features 3SBio Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate 3SBio Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for 3SBio Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 3SBio Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 3SBio Inc. Snapshot 7 3SBio Inc. Overview 7 Key Information 7 Key Facts 7 3SBio Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 3SBio Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 3SBio Inc. - Pipeline Products Glance 16 3SBio Inc. - Late Stage Pipeline Products 16 Phase III Products/Combination Treatment Modalities 16 3SBio Inc. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 3SBio Inc. - Early Stage Pipeline Products 19 IND/CTA Filed Products/Combination Treatment Modalities 19 Preclinical Products/Combination Treatment Modalities 20 3SBio Inc. - Drug Profiles 21 (clindamycin phosphate + tretinoin) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 AT-101 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 SSS-06 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 SSS-07 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 (tipiracil hydrochloride + trifluridine) 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 cinacalcet hydrochloride 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 colestilan chloride 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 eltrombopag olamine 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 nadroparin calcium 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PEG-EPO 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PEG-irinotecan 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 pegadricase 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 sevelamer carbonate 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 trelagliptin succinate 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 (betamethasone valerate + calcipotriene) 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 APG-1387 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 desonide 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 DJ-5 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 DNP-001 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ferric citrate 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 fondaparinux sodium 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 PMC-001 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecule to Inhibit HIF-PH for Renal Anemia 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 SSS-08 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 thrombopoietin 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 TTAC-0001 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 3SBio Inc. - Pipeline Analysis 55 3SBio Inc. - Pipeline Products by Target 55 3SBio Inc. - Pipeline Products by Route of Administration 57 3SBio Inc. - Pipeline Products by Molecule Type 58 3SBio Inc. - Pipeline Products by Mechanism of Action 59 3SBio Inc. - Recent Pipeline Updates 61 3SBio Inc. - Dormant Projects 75 3SBio Inc. - Discontinued Pipeline Products 76 Discontinued Pipeline Product Profiles 76 NuLeusin 76 3SBio Inc. - Company Statement 77 3SBio Inc. - Locations And Subsidiaries 78 Head Office 78 Other Locations & Subsidiaries 78 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
3SBio Inc., Key Information 7 3SBio Inc., Key Facts 7 3SBio Inc. - Pipeline by Indication, 2016 9 3SBio Inc. - Pipeline by Stage of Development, 2016 11 3SBio Inc. - Monotherapy Products in Pipeline, 2016 12 3SBio Inc. - Combination Treatment Modalities in Pipeline, 2016 13 3SBio Inc. - Partnered Products in Pipeline, 2016 14 3SBio Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15 3SBio Inc. - Phase III, 2016 16 3SBio Inc. - Phase II, 2016 17 3SBio Inc. - Phase I, 2016 18 3SBio Inc. - IND/CTA Filed, 2016 19 3SBio Inc. - Preclinical, 2016 20 3SBio Inc. - Pipeline by Target, 2016 55 3SBio Inc. - Pipeline by Route of Administration, 2016 57 3SBio Inc. - Pipeline by Molecule Type, 2016 58 3SBio Inc. - Pipeline Products by Mechanism of Action, 2016 60 3SBio Inc. - Recent Pipeline Updates, 2016 61 3SBio Inc. - Dormant Developmental Projects,2016 75 3SBio Inc. - Discontinued Pipeline Products, 2016 76 3SBio Inc., Other Locations 78 3SBio Inc., Subsidiaries 79


List of Figures
3SBio Inc. - Pipeline by Top 10 Indication, 2016 9 3SBio Inc. - Pipeline by Stage of Development, 2016 11 3SBio Inc. - Monotherapy Products in Pipeline, 2016 12 3SBio Inc. - Combination Treatment Modalities in Pipeline, 2016 13 3SBio Inc. - Partnered Products in Pipeline, 2016 14 3SBio Inc. - Pipeline by Top 10 Target, 2016 55 3SBio Inc. - Pipeline by Route of Administration, 2016 57 3SBio Inc. - Pipeline by Molecule Type, 2016 58 3SBio Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 59

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...
Choose License Type
Single User - US $1500
Multi User - US $3000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify